Pharmafile Logo

vs.MS

Design-thinking. Iterating for continuous improvement.

How design can lead improvement within Pharma

Mednet Group

- PMLiVE

Roche reports positive results for drug for relapsing forms of MS

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE

MS charities urge UK government to improve patient mental health support

Around 130,000 people in the UK have MS with half dealing with depression at some stage

- PMLiVE

MS Awareness Week 2023 runs from 24-30 April with seven UK MS charities joining forces

Approximately 130,000 people in the UK are living with the disease

- PMLiVE

Oxford PharmaGenesis wins King’s Award following rapid export growth

Oxford PharmaGenesis has been honoured with the first ever King’s Award for Enterprise, the most prestigious business award in the country.

Oxford PharmaGenesis

- PMLiVE

Novartis announces positive long-term data for relapsing MS treatment Kesimpta

Approximately 85% of MS patients are initially diagnosed with relapsing forms of the disease

- PMLiVE

Merck KGaA’s MS drug put on partial clinical hold by FDA

Laboratory results suggested there were two cases of drug-induced liver injury during the phase 3 studies

- PMLiVE

UK launches ‘revolutionary’ trial for progressive MS patients

Octopus is assessing whether existing drugs can be used to help slow disease progression

- PMLiVE

Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes

Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech...

Avalere Health

Rare Diseases on Medscape Education: Long-Chain Fatty Acid Oxidation Disorder

Rare Disease Day may be over but our committment to advancing outcomes for patients continues. Listen to a mother explain her daughter's journey with a long-chain fatty acid oxidation disorder.To...

Medscape Education Global

- PMLiVE

Sanofi reports positive new data for multiple sclerosis treatment tolebrutinib

It is estimated that there are over 130,000 people living with the condition in the UK alone

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links